Electrolyte Complications of Malignancy

Emergency Medicine Clinics of North America

Volumn 27, Issue 2, 2009, Pages 257-269

  Kacprowicz, Robert F ^a,b,c   Lloyd, Jeremy D ^a,c  

^a San Antonio Uniformed Services Health Education Consortium Emergency Medicine Residency   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Electrolytes; Hypercalcemia; Hyperphosphatemia; Hypoglycemia; Hyponatremia; Malignancy

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CARBOPLATIN; CINACALCET; CISPLATIN; CONIVAPTAN; GALLIUM NITRATE; GLUCOCORTICOID; GLUCOSE; LITHIUM; MAGNESIUM; MAGNESIUM SULFATE; MITHRAMYCIN; OSTEOPROTEGERIN; PAMIDRONIC ACID; PHOSPHATE; POTASSIUM DIHYDROGEN PHOSPHATE; PREDNISONE; SALCATONIN; SOMATOSTATIN DERIVATIVE; STEROID; THIAZIDE DIURETIC AGENT; VASOPRESSIN; VITAMIN D; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADRENAL INSUFFICIENCY; ADRENAL METASTASIS; BLOOD CLOTTING DISORDER; BONE PAIN; CALCIUM EXCRETION; CALCIUM INTAKE; CENTRAL PONTINE MYELINOLYSIS; CEREBRAL SALT WASTING; CLINICAL FEATURE; CONJUNCTIVITIS; CONTINUOUS INFUSION; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DIZZINESS; DRUG MECHANISM; DRUG POTENTIATION; ELECTROLYTE DISTURBANCE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMORAL HYPERCALCEMIA OF MALIGNANCY; HYPERCALCEMIA; HYPERCALCEMIA OF MALIGNANCY; HYPERCALCEMIA OF PREGNANCY; HYPERKALEMIA; HYPERNATREMIA; HYPERPHOSPHATEMIA; HYPERVOLEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INAPPROPRIATE VASOPRESSIN SECRETION; INSULIN RELEASE; INSULINOMA; IRIDOCYCLITIS; JAW OSTEONECROSIS; KIDNEY FAILURE; LIVER METASTASIS; LIVER TOXICITY; LUNG INFILTRATE; LUNG SMALL CELL CANCER; NAUSEA; NEOPLASM; NEPHROTOXICITY; NONISLET CELL TUMOR HYPOGLYCEMIA; OPTIC NEURITIS; ORTHOSTATIC DIZZINESS; OSMOTIC DEMYELINATION SYNDROME; PLEURA EFFUSION; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SCLERITIS; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR ASSOCIATED HYPOGLYCEMIA;

EID: 65549133039     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2009.01.007     Document Type: Review

References (51)

1. Lee C.T., Guo H.R., and Chen J.B. Hyponatremia in the emergency department. Am J Emerg Med 18 (2000) 264-268
2. Sverha J.J., and Borenstein M. Emergency complications of malignancy. In: Tintinalli J., Kelen G.D., and Stapcyzinski J.S. (Eds). Emergency medicine: a comprehensive study guide. 5th edition (2000), McGraw-Hill, New York 1408-1414
3. Cao L., Prashant J., and Sumoza D. Renal salt wasting in a patient with cisplatin-induced hyponatremia. Am J Clin Oncol 25 (2002) 344-346
4. Sorensen J.B., Andersen M.K., and Hansen H.H. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 238 (1995) 97-110
5. Johnson B.E., Chute J.P., Rushin J., et al. A prospective study of patients with lung cancer and hyponatremia of malignancy. Am J Respir Crit Care Med 156 (1997) 1669-1678
6. Verbalis J.G., Goldsmith S.R., Greenberg A., et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 120 (2007) S1-S21
7. Yeong-Hau L.H., and Shapiro J.I. Hyponatremia: clinical diagnosis and management. Am J Med 120 (2007) 653-658
8. Vassal G., Rubie C., Kalifa C., et al. Hyponatremia and renal sodium wasting in patients receiving cisplatinum. Pediatr Hematol Oncol 4 (1987) 337-344
9. Arieff A., Llach F., and Massey S.G. Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes. Medicine 55 (1976) 121-129
10. Lauriat S.M., and Berl T. The hyponatremic patient: practical focus on therapy. J Am Soc Nephrol 8 (1997) 1599-1607
11. Sterns R.H. Severe symptomatic hyponatremia: treatment and outcome. A study of 64 cases. Ann Intern Med 107 (1987) 656-664
12. Decaux G., and Soupart A. Treatment of symptomatic hyponatremia. Am J Med Sci 326 1 (2003) 25-30
13. Adams R.D., Victor M., and Mancall E.D. Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients. AMA Arch Neurol Psychiatry 81 2 (1959) 154-172
14. Wright D.G., Laureno R., and Victor M. Pontine and extrapontine myelinolysis. Brain 102 (1979) 361-365
15. Rabinstein A.A., and Wijdicks E.F. Hyponatremia in critically ill neurological patients. Neurologist 9 6 (2003) 290-300
16. Yancey P.H., Clark M.E., Hand S.C., et al. Living with water stress: evolution of osmolyte systems. Science 217 (1982) 1214-1222
17. Lien Y.H. Role of organic osmolytes in myelinolysis. A topographic study in rats after rapid correction of hyponatremia. J Clin Invest 95 (1995) 1579-1586
18. Soupart A., and Decaux G. Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications. Clin Nephrol 46 (1996) 149-169
19. Laureno R. Central pontine myelinolysis following rapid correction of hyponatremia. Ann Neurol 13 (1983) 232-242
20. Soupart A., Ngassa M., and Decaux G. Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia. Clin Nephrol 51 (1999) 383-386
21. Knepper M.A. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Phys 272 (1997) F3-F12
22. Verbalis J.G., Bisaha J.G., and Smith N. Novel vasopressin V1A and V2 antagonist (conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia. J Card Fail 10 Suppl 4 (2004) S27
23. Ghali J.K., Koren M.J., Taylor J.R., et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 91 6 (2006) 2145-2152
24. Vaprisol (package insert) (2005), Astellas Pharma US, Deerfield (IL)
25. Oh M. Management of hyponatremia and clinical use of vasopressin antagonists. Am J Med Sci 332 (2007) 101-105
26. Nayar M.K., Lombard M.G., Furlong N.J., et al. Diagnosis and management of non-islet cell tumor hypoglycemia. Endocrinologist 16 4 (2006) 227-230
27. Service F.J. Hypoglycemic disorders. N Engl J Med 91 (1995) 505-510
28. de Groot J.W., Rikhof B., van Doorn J., et al. Non-islet cell tumour induced hypoglycaemia: a review of the literature including two new cases. Endocr Relat Cancer 14 (2007) 979-993
29. Le Roith D. Tumor-induced hypoglycemia. N Engl J Med 341 (1999) 757-758
30. Marks V., and Teale J.D. Tumours producing hypoglycaemia. Endocr Relat Cancer 5 (1998) 111-129
31. Daughaday W.H., and Trivedi B. Measurement of derivatives of proinsulin-like growth factor-II in serum by radioimmunoassay directed against the E-domain in normal subjects and patients with nonislet cell tumor hypoglycemia. J Clin Endocrinol Metab 75 (1992) 110-115
32. Strewler G.J. Humoral manifestations of malignancy. In: Kronenberg H.M., Shlomo M., Polonsky K.S., et al. (Eds). Williams textbook of endocrinology. 11th edition (2008), Saunders, Philadelphia 1803-1817
33. Mundy G.R., and Guise T.A. Hypercalcemia of malignancy. Am J Med 103 (1997) 134-145
34. Ralston S.H., Gallagher S.J., Patel U., et al. Cancer associated hypercalcemia: morbidity and mortality: clinical experience in 126 treated patients. Ann Intern Med 112 (1990) 499-504
35. Barri Y.M., and Knochei J.P. Hypercalcemia and electrolyte disturbances in malignancy. Hematol Oncol Clin North Am 10 (1996) 775-780
36. Stewart A.F. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352 4 (2005) 373-379
37. Nussbaum S.R., Gaz R.D., and Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 323 (1990) 1324-1328
38. Ladenson J.H., Lewis J.W., McDonald J.M., et al. Relationship of free and total calcium in hypercalcemic conditions. J Clin Endocrinol Metab 48 (1978) 393-397
39. Shepard M.M., and Smith J.W. Hypercalcemia. Am J Med Sci 334 5 (2007) 381-385
40. Body J.J. Current and future directions in medical therapy: hypercalcemia. Cancer 88 (2000) 3054-3058
41. Layman R., Olson K., and Van Poznak C. Bisphosphonates for breast cancer. Hematol Oncol Clin North Am 21 2 (2007) 341-367
42. Koo W.S., Jeon D.S., Ahn S.J., et al. Calcium-free hemodialysis for the management of hypercalcemia. Nephron 72 (1996) 424-428
43. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 10 (2006) 753-761
44. Ariyan C.E., and Sosa J.A. Assessment and management of patients with abnormal calcium. Crit Care Med 32 (2004) S146-S154
45. Kinirons M.T. Newer agents for the treatment of malignant hypercalcemia. Am J Med Sci 305 (1993) 403-406
46. Morony S., Warmington K., Adamu S., et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 146 (2005) 3235-3243
47. Shoback D. Cinacalcet hydrochloride reduces hypercalcemia in patients with parathyroid carcinoma. Nat Clin Pract Endocrinol Metab 3 12 (2007) 794
48. Gibbs M.A., and Tayal V.S. Electrolyte disturbances. In: Marx J.A., Hockberger R.S., Walls R.M., et al. (Eds). Rosen's emergency medicine: concepts and clinical practice. 6th edition (2006), Saunders, Philadelphia 1933-1953
49. Taylor B.E., Huey W.Y., Buchman T.G., et al. Treatment of hypophosphatemia using a protocol based on patient weight and serum phosphorus level in a surgical intensive care unit. J Am Coll Surg 198 2 (2004) 198-204
50. Charron T., Bernard F., and Skrobik Y. Intravenous phosphate in the intensive care unit: more aggressive repletion regimens for moderate and severe hypophosphatemia. Intensive Care Med 29 8 (2003) 1273-1278
51. Gaasbeek A. Hypophosphatemia: an update on its etiology and treatment. Am J Med 118 10 (2005) 1094-1101